Merck CEO Says Company Will Seek Approval for Drug to Reverse Anesthesia
Kenneth Frazier, the CEO of drug manufacturer Merck, says the company will seek approval for a drug that reverses anesthesia after surgery in 2012, according to a Bloomberg Businessweek report.
Mr. Frazier has had a rocky first year with the company. Last Jan. 2011, after he took the helm, Merck unexpectedly ended a late-stage study of a blood thinner due to bleeding risks. Merck's return to shareholders dropped to the lowest in the industry after problems delayed other drugs.
Mr. Frazier said the company will seek approval for Bridion, a drug for reversing anesthesia that is approved in many other countries but was rejected in the U.S. in 2008.
Related Articles on Anesthesia:
Anesthesiologist Who Treated JFK in Dallas ER Dies at 79
Surgery With Anesthesia May Prompt Memory Loss Cognitive Decline
Minneapolis Hospital Mistakenly Gives Surgery Patient Paralyzing Anesthetic
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
Latest Articles
- Distraction Reduces Perceived Pain
- Study: Nucynta Effective Pain Reliever for Diabetic Peripheral Neuropathy
- American Board of Internal Medicine Discusses Initiative to Limit Medical Tests
- Disciplinary Actions From State Medical Boards Increase
- Two Anesthesiologists Selected to Lead St. Joseph Medical Center Anesthesia Department
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,369.38 Trade time:4:03PM EDT Value change:▼73.11 (-0.59%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,778.79 Trade time:5:16PM EDT Value change:▼34.90 (-1.24%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,295.22 Trade time:4:33PM EDT Value change:▼9.64 (-0.74%)Channels
